Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials

Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials

Targeted therapies such as oral tyrosine kinase inhibitors (TKIs) are the main therapeutic strategy effective for advanced hepatocellular carcinoma (HCC). Currently six tyrosine kinase inhibitors for HCC therapy have been approved. The newly approved first-line drug donafenib represent the major mil...

Full description

Bibliographic Details
Main Authors: Lisha Mou, Xiaohe Tian, Bo Zhou, Yongqiang Zhan, Jiao Chen, Ying Lu, Jing Deng, Ying Deng, Zijing Wu, Qi Li, Yi’an Song, Hongyuan Zhang, Jinjun Chen, Kuifeng Tian, Yong Ni, Zuhui Pu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Oncology
Subjects:
sorafenib
lenvatinib
tyrosine kinase inhibitors
TKIs
hepatocellular carcinoma
HCC
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.752725/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.752725/full

Similar Items